21 results on '"Nakamura, Yoshiaki"'
Search Results
2. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
- Author
-
Osumi, Hiroki, Shinozaki, Eiji, Nakamura, Yoshiaki, Esaki, Taito, Yasui, Hisateru, Taniguchi, Hiroya, Satake, Hironaga, Sunakawa, Yu, Komatsu, Yoshito, Kagawa, Yoshinori, Denda, Tadamichi, Shiozawa, Manabu, Satoh, Taroh, Nishina, Tomohiro, Goto, Masahiro, Takahashi, Naoki, Kato, Takeshi, Bando, Hideaki, Yamaguchi, Kensei, and Yoshino, Takayuki
- Subjects
COLORECTAL cancer ,METASTASIS ,CIRCULATING tumor DNA ,LYMPHATIC metastasis ,NUCLEOTIDE sequencing - Abstract
"NeoRAS WT" refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequencing of plasma circulating tumor DNA. Patients with mCRC enrolled in the GOZILA study initially diagnosed with tissue RAS MT mCRC and received subsequent systemic therapy are eligible. NeoRAS WT is defined as the absence of detectable RAS MT in plasma and assessed in all eligible patients (Group A) and in a subgroup with at least one somatic alteration detected in plasma (Group B). Overall, 478 patients are included. NeoRAS WT prevalence is 19.0% (91/478) in Group A and 9.8% (42/429) in Group B. Absence of liver or lymph node metastasis and tissue RAS MTs other than KRAS exon 2 MTs are significantly associated with NeoRAS WT emergence. Overall, 1/6 and 2/6 patients with NeoRAS WT treated with anti-EGFR monoclonal antibodies (mAbs) show partial response and stable disease for ≥6 months, respectively. NeoRAS WT mCRC is observed at a meaningful prevalence, and anti-EGFR mAb-based therapy may be effective. RAS mutations have been shown to be lost after first line treatment for metastatic colorectal cancer. Here, the authors leverage the GOZILA study to identify these patients and identify their association with other risk factor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
- Author
-
Kajiwara, Takeshi, Nishina, Tomohiro, Yamashita, Riu, Nakamura, Yoshiaki, Shiozawa, Manabu, Yuki, Satoshi, Taniguchi, Hiroya, Hara, Hiroki, Ohta, Takashi, Esaki, Taito, Shinozaki, Eiji, Takashima, Atsuo, Yamamoto, Yoshiyuki, Yamazaki, Kentaro, Yoshino, Takayuki, and Hyodo, Ichinosuke
- Subjects
SEQUENCE analysis ,MULTIVARIATE analysis ,METASTASIS ,EARLY detection of cancer ,GAIN-of-function mutations ,COLORECTAL cancer ,GENES ,RESEARCH funding ,OVERALL survival - Abstract
Simple Summary: The treatment strategies and prognoses of patients with metastatic colorectal cancer differ according to the sidedness of the primary tumor. The aim of this study was to evaluate the sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer. Among patients diagnosed with metastatic colorectal cancer enrolled from April 2017 to March 2019, 531 patients who underwent complete gene sequencing were assessed. TP53 gain-of-function and KRAS variants were poor prognostic factors, while the NOTCH3 sole variant was a favorable prognostic factor for left-sided metastatic colorectal cancer. The TP53 non-gain-of-function variant, BRAF V600E, and MYC amplification were poor prognostic factors for right-sided metastatic colon cancer. Prognostic gene alterations in metastatic colorectal cancer differed according to the sidedness of the primary tumor. The treatment strategies and prognoses of patients with metastatic colorectal cancer (CRC) differ according to the sidedness of the primary tumor. TP53 gain-of-function (GOF) and non-GOF variants have been reported to be differentially associated with prognosis by sidedness. We aimed to evaluate the sidedness-dependent prognostic impact of gene alterations in metastatic CRC. Patients enrolled between April 2017 and March 2019 were included in this study. Those excluded were individuals whose tumor tissues were obtained after chemotherapy and those who were enrolled in the study more than six months after starting first-line chemotherapy. Finally, we assessed 531 patients who underwent complete gene sequencing. The study revealed a significant difference in overall survival between individuals with left-sided CRC (n = 355) and right-sided colon cancer (CC) (n = 176) when considering the TP53 non-GOF variant, KRAS wild-type, NOTCH1 wild-type, NOTCH1 covariant, NOTCH3 sole variant, and MYC amplification. Multivariate analysis on each side revealed that the TP53 GOF and KRAS variants were independent poor prognostic factors for left-sided CRC (p = 0.03 and p < 0.01, respectively), and the TP53 non-GOF variant, BRAF V600E, and MYC amplification for right-sided CC (p < 0.05, p < 0.01, and p = 0.02, respectively). The NOTCH3 sole variant was an independent and favorable prognostic factor for left-sided CRC (p < 0.01). The prognostic significance of gene alterations differed between left-sided CRC and right-sided CC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.
- Author
-
Aoki, Yu, Nakamura, Yoshiaki, Denda, Tadamichi, Ohta, Takashi, Esaki, Taito, Shiozawa, Manabu, Yamaguchi, Kensei, Yamazaki, Kentaro, Sunakawa, Yu, Kato, Takeshi, Okano, Naohiro, Taniguchi, Hiroya, Sato, Taro, Oki, Eiji, Nishina, Tomohiro, Komatsu, Yoshito, Matsuhashi, Nobuhisa, Goto, Masahiro, Yasui, Hisateru, and Ohtsubo, Koushiro
- Subjects
- *
COLORECTAL cancer , *BRAF genes , *CIRCULATING tumor DNA , *METASTASIS , *BLOOD collection , *HEREDITARY nonpolyposis colorectal cancer - Abstract
PURPOSE: Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, the validity of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment and the efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA results remains unclear. PATIENTS AND METHODS: The performance of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment was compared with that of a validated polymerase chain reaction–based tissue testing in patients with mCRC enrolled in the GOZILA study, a nationwide plasma genotyping study. The primary end points were concordance rate, sensitivity, and specificity. The efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA were also evaluated. RESULTS: In 212 eligible patients, the concordance rate, sensitivity, and specificity were 92.9% (95% CI, 88.6 to 96.0), 88.7% (95% CI, 81.1 to 94.0), and 97.2% (95% CI, 92.0 to 99.4) for RAS and 96.2% (95% CI, 92.7 to 98.4), 88.0% (95% CI, 68.8 to 97.5), and 97.3% (95% CI, 93.9 to 99.1) for BRAF V600E, respectively. In patients with a ctDNA fraction of ≥1.0%, sensitivity rose to 97.5% (95% CI, 91.2 to 99.7) and 100% (95% CI, 80.5 to 100.0) for RAS and BRAF V600E mutations, respectively. In addition to a low ctDNA fraction, previous chemotherapy, lung and peritoneal metastases, and interval between dates of tissue and blood collection were associated with discordance. The progression-free survival of anti-EGFR therapy and BRAF-targeted treatment was 12.9 months (95% CI, 8.1 to 18.5) and 3.7 (95% CI, 1.3 to not evaluated) months, respectively, for matched patients with RAS/BRAF V600E results by ctDNA. CONCLUSION: ctDNA genotyping effectively detected RAS/BRAF mutations, especially with sufficient ctDNA shedding. Clinical outcomes support ctDNA genotyping for determining the use of anti-EGFR and BRAF-targeted therapies in patients with mCRC. Using a large-scale plasma genomic profiling program (SCRUM-Japan GOZILA), we validated ctDNA genotyping for RAS and BRAF V600E in metastatic colorectal cancer comparing with a validated tissue PCR-based testing. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer.
- Author
-
Yoshikawa, Ayumu and Nakamura, Yoshiaki
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *DRUG efficacy , *SEQUENCE analysis , *DNA , *ONCOGENES , *EPIDERMAL growth factor receptors , *TRASTUZUMAB , *METASTASIS , *CELL receptors , *DRUG resistance , *COLORECTAL cancer , *GENE expression , *TUMOR markers , *BLOOD - Abstract
Simple Summary: Human epidermal growth factor receptor 2 (HER2) amplification has emerged as a biomarker of metastatic colorectal cancer (mCRC). Prospective clinical trials have demonstrated the efficacy of HER2-targeted therapies for HER2-positive mCRC and explored the underlying mechanisms. To improve the therapeutic efficacy of this strategy, many clinical trials with various HER2-targeted agents are ongoing. This review discusses the molecular basis of HER2-targeted therapeutic strategies for patients with HER2-positive mCRC. Human epidermal growth factor receptor 2 (HER2) amplification has emerged as a biomarker in colorectal cancer (CRC), occurring in 1–4% of metastatic CRC (mCRC). In addition to conventional methods, such as immunohistochemistry and fluorescence in situ hybridization, next-generation sequencing-based tissue or circulating tumor DNA analysis has recently been used to identify HER2 amplification and assess HER2 overexpression. Prospective clinical trials have demonstrated the efficacy of HER2-targeted therapies in HER2-positive mCRC. The TRIUMPH study, a phase II study of dual HER2 antibodies, i.e., pertuzumab plus trastuzumab, demonstrated promising efficacy for patients with HER2-positive mCRC confirmed by tissue-and/or blood-based techniques, which led to the regulatory approval of this combination therapy in Japan. The mechanisms associated with efficacy and resistance have also been explored in translational studies that incorporate liquid biopsy in prospective trials. In particular, HER2 copy number and co-alterations have repeatedly been reported as biomarkers related to efficacy. To improve the therapeutic efficacy of the current strategy, many clinical trials with various HER2-targeted agents are ongoing. This review discusses the molecular basis of HER2-targeted therapeutic strategies for patients with HER2-positive mCRC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
- Author
-
Bando, Hideaki, Nakamura, Yoshiaki, Taniguchi, Hiroya, Shiozawa, Manabu, Yasui, Hisateru, Esaki, Taito, Kagawa, Yoshinori, Denda, Tadamichi, Satoh, Taroh, Yamazaki, Kentaro, Sunakawa, Yu, Kato, Takeshi, Goto, Masahiro, Yuki, Satoshi, Nishina, Tomohiro, Oki, Eiji, Shinozaki, Eiji, Matsuhashi, Nobuhisa, Takahashi, Naoki, and Tsuji, Akihito
- Subjects
- *
CIRCULATING tumor DNA , *COLORECTAL cancer , *METASTASIS , *NUCLEOTIDE sequencing , *KRUSKAL-Wallis Test - Abstract
PURPOSE: Low concordance between plasma-based and tissue-based tests for determining the RAS mutational status have been reported in some but not all patients with limited-extent metastatic colorectal cancer (mCRC). In this study, we investigated the relationship between metastatic site and circulating tumor DNA (ctDNA) detection using ctDNA genotyping, an alternative to tissue genotyping for precision oncology. MATERIALS AND METHODS: We investigated the relationship between metastatic site and ctDNA detection using Guardant360, a next-generation sequencing ctDNA assay, in mCRC patients with single-organ metastasis in the SCRUM-Japan GOZILA study (UMIN000029315). RESULTS: Of 1,187 patients with mCRC enrolled in GOZILA, 138 were eligible (49 with liver-only, 15 with lymph node-only, 27 with peritoneum-only, and 47 with lung-only metastases). The concordance of RAS / BRAF status between Guaradant360 and tissue in vitro diagnostic tests was 95.9% in patients with liver-only, 80.0% in lymph node-only, 56.0% in peritoneum-only, and 65.9% in lung-only metastases. ctDNA fraction, as measured by the median maximum variant allelic fraction (max VAF), and median number of detected variants were 23.1% and five in liver-only, 6.0% and five in lymph node-only, 0.4% and three in peritoneum-only, and 0.4% and three in lung-only metastases, respectively (all P <.001, Kruskal-Wallis test). Few patients with liver-only (2.0%) and lymph node-only metastasis (13.3%) had a max VAF < 0.2%, which is required to ensure a detection limit of 95%, but max VAF was more frequently < 0.2% in patients with lung-only (27.7%) or peritoneum-only metastasis (29.6%). CONCLUSION: Patients with lung-only and peritoneum-only metastatic disease have significantly lower levels of ctDNA, suggesting decreased clinical sensitivity for subclonal variants. This observation suggests that such patients may benefit from concurrent tissue and plasma testing to provide optimal genotyping for subsequent therapy selection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database.
- Author
-
Nakamura, Yoshiaki, Olsen, Steven, Zhang, Nicole, Liao, Jiemin, and Yoshino, Takayuki
- Subjects
- *
GENOMES , *CIRCULATING tumor DNA , *COLORECTAL cancer , *MEDICAL care , *CHLOROPLAST DNA - Abstract
We used a real-world database (GuardantINFORMTM) to analyze the treatment choices for patients with mCRC who underwent next-generation sequencing of circulating tumor DNA (ctDNA) using a commercially available test (Guardant360®) after first- or second-line therapy. From 18,875 patients with claims for CRC, 1064 had confirmed metastatic disease and sufficient histories for analysis (median age 59 years, 44.8% female, 44.5% left-sided). ctDNA was detectable for 997/1064 (93.7%) patients. Clinically actionable molecular profiles were present for 507/1064 (47.7%) patients, including those who had not received targeted therapy in the previous line (410/926, 44.3%). Second- or third-line targeted therapies were administered to 338/1064 patients (31.8%) and were considered matched for 193/338 (57.1%) patients. Therapies administered after testing were informed by the ctDNA results in 56.7% of patients overall (603/1064). Time to treatment discontinuation was most favorable for patients with a clinically actionable ctDNA profile who received matched therapy. This analysis demonstrates the real-world clinical value of plasma-based comprehensive genomic profiling for selecting appropriate molecular-targeted therapies in mCRC patients with disease progression after first- or second-line therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy.
- Author
-
Miyo, Masaaki, Kato, Takeshi, Nakamura, Yoshiaki, Taniguchi, Hiroya, Takahashi, Yusuke, Ishii, Masayuki, Okita, Kenji, Ando, Koji, Yukami, Hiroki, Mishima, Saori, Yamazaki, Kentaro, Kotaka, Masahito, Watanabe, Jun, Oba, Koji, Aleshin, Alexey, Billings, Paul R., Rabinowitz, Matthew, Kotani, Daisuke, Oki, Eiji, and Takemasa, Ichiro
- Abstract
According to the current international guidelines, high‐risk patients diagnosed with pathological T1 (pT1) colorectal cancer (CRC) who underwent complete local resection but may have risk of developing lymph node metastasis (LNM) are recommended additional intestinal resection with lymph node dissection. However, around 90% of the patients without LNM are exposed to the risk of being overtreated due to the insufficient pathological criteria for risk stratification of LNM. Circulating tumor DNA (ctDNA) is a noninvasive biomarker for molecular residual disease and relapse detection after treatments including surgical and endoscopic resection of solid tumors. The CIRCULATE‐Japan project includes a large‐scale patient‐screening registry of the GALAXY study to track ctDNA status of patients with stage II to IV or recurrent CRC that can be completely resected. Based on the CIRCULATE‐Japan platform, we launched DENEB, a new prospective study, within the GALAXY study for patients with pT1 CRC who underwent complete local resection and were scheduled for additional intestinal resection with lymph node dissection based on the standard pathologic risk stratification criteria for LNM. The aim of this study is to explore the ability of predicting LNM using ctDNA analysis compared with the standard pathological criteria. The ctDNA assay will build new evidence to establish a noninvasive personalized diagnosis in patients, which will facilitate tailored/optimal treatment strategies for CRC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
- Author
-
Taniguchi, Hiroya, Nakamura, Yoshiaki, Kotani, Daisuke, Yukami, Hiroki, Mishima, Saori, Sawada, Kentaro, Shirasu, Hiromichi, Ebi, Hiromichi, Yamanaka, Takeharu, Aleshin, Alexey, Billings, Paul R., Rabinowitz, Matthew, Oki, Eiji, Takemasa, Ichiro, Kato, Takeshi, Mori, Masaki, and Yoshino, Takayuki
- Abstract
Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) prior to and post surgery has been reported across various solid tumors. We initiated a new type of adaptive platform trials to evaluate the clinical benefits of ctDNA analysis and refine precision adjuvant therapy for resectable colorectal cancer, named CIRCULATE‐Japan including three clinical trials. The GALAXY study is a prospectively conducted large‐scale registry designed to monitor ctDNA for patients with clinical stage II to IV or recurrent colorectal cancer who can undergo complete surgical resection. The VEGA trial is a randomized phase III study designed to test whether postoperative surgery alone is noninferior to the standard therapy with capecitabine plus oxaliplatin for 3 months in patients with high‐risk stage II or low‐risk stage III colon cancer if ctDNA status is negative at week 4 after curative surgery in the GALAXY study. The ALTAIR trial is a double‐blind, phase III study designed to establish the superiority of trifluridine/tipiracil as compared with placebo in patients with resected colorectal cancer who show circulating tumor–positive status in the GALAXY study. Therefore, CIRCULATE‐Japan encompasses both "de‐escalation" and "escalation" trials for ctDNA‐negative and ‐positive patients, respectively, and helps to answer whether measuring ctDNA postoperatively has prognostic and/or predictive value. Our ctDNA‐guided adaptive platform trials will accelerate clinical development toward further precision oncology in the field of adjuvant therapy. Analysis of ctDNA status could be utilized as a predictor of risk stratification for recurrence and to monitor the effectiveness of adjuvant chemotherapy. ctDNA is a promising, noninvasive tumor biomarker that can aid in tumor monitoring throughout disease management. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
- Author
-
Nakajima, Hiromichi, Kotani, Daisuke, Bando, Hideaki, Kato, Takeshi, Oki, Eiji, Shinozaki, Eiji, Sunakawa, Yu, Yamazaki, Kentaro, Yuki, Satoshi, Nakamura, Yoshiaki, Yamanaka, Takeharu, Yoshino, Takayuki, Ohta, Takashi, Taniguchi, Hiroya, and Kagawa, Yoshinori
- Subjects
COLORECTAL cancer ,EPIDERMAL growth factor receptors ,CIRCULATING tumor DNA ,METASTASIS ,IRINOTECAN ,PANITUMUMAB - Abstract
Background: Previous clinical trials have demonstrated the potential efficacy of rechallenge with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer (mCRC). Moreover, post hoc biomarker analyses of clinical trials has suggested that RAS status in circulating tumor DNA (ctDNA) has a high probability to select patients who could benefit from anti-EGFR mAb rechallenge.Methods: This trial is composed of 2 phases: a monitoring phase (REMARRY) and a trial phase (PURSUIT). A monitoring phase, the REMARRY study, aims to evaluate the dynamics of plasma RAS status during the subsequent treatments after refractory to anti-EGFR therapy in patients with mCRC with RAS/BRAF V600E wild-type tumors who have progressed after a response to previous anti-EGFR therapy, using a highly sensitive digital polymerase chain reaction OncoBEAM RAS CRC kit in a central laboratory (Sysmex, Japan). A trial phase, the PURSUIT trial, is a multicenter, single-arm phase II trial to assess the efficacy and safety of rechallenge therapy with panitumumab plus irinotecan in patients without RAS mutations in ctDNA (plasma RAS negative) in the REMARRY study. Key eligibility criteria of the PURSUIT trial include RAS/BRAF V600E wild-type mCRC in tumor tissue refractory or intolerant to fluoropyrimidine, oxaliplatin, and irinotecan; progression after complete or partial response to previous anti-EGFR therapy; plasma RAS negative (defined as plasma mutant allele frequencies [MAF] of all RAS ≤ 0.1%) within 28 days prior to enrollment; 4 months or more between the last administration of previous anti-EGFR mAb and the start of protocol treatment; and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1. The primary endpoint is the confirmed objective response rate (ORR). The target sample size of the PURSUIT trial is 50 patients. Biomarker analyses will be performed in parallel using the OncoBEAM RAS CRC kit and a next-generation sequencing-based ctDNA analysis (Guardant360).Discussion: Our trial aims to confirm the clinical benefit of anti-EGFR mAb rechallenge therapy in patients with plasma RAS negative. Moreover, through biomarker analyses, our trial will shed light on which patients would benefit from rechallenge in addition to being plasma RAS negative.Trial Registration: The REMARRY study: UMIN, UMIN000036424 . Registered date: April 5, 2019. The PURSUIT trial: jRCT, jRCTs031190096 . Registered date: October 1, 2019. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.
- Author
-
Chida, Keigo, Kotani, Daisuke, Nakamura, Yoshiaki, Kawazoe, Akihito, Kuboki, Yasutoshi, Shitara, Kohei, Kojima, Takashi, Taniguchi, Hiroya, Watanabe, Jun, Endo, Itaru, and Yoshino, Takayuki
- Abstract
Background: The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, there had been no direct comparative phase III trial to compare the efficacy between TAS102 plus BEV and standard therapy with either TAS102 or regorafenib monotherapy. Methods: We retrospectively reviewed the medical records of patients with mCRC who received TAS102 plus BEV, TAS102 monotherapy, or regorafenib monotherapy after standard chemotherapies during 2013–2019. Results: Patients received TAS102 plus BEV (n = 139), TAS102 monotherapy (n = 153), or regorafenib monotherapy (n = 133). With a median follow-up of 25.3 months, median overall survival (OS) was 11.5 months [95% confidence interval (CI), 9.9–13.9] for TAS102 plus BEV, 8.1 months (95% CI, 6.8–9.2) for TAS102 monotherapy, and 6.8 months (95% CI, 5.7–8.5) for regorafenib monotherapy. The hazard ratios were 0.67 (95% CI, 0.51–0.88) for TAS102 plus BEV versus TAS102 monotherapy and 0.71 (95% CI, 0.54–0.94) for TAS102 plus BEV versus regorafenib monotherapy. Median progression-free survival (PFS) was 4.4 months (95% CI, 3.7–5.4) for TAS102 plus BEV, 2.5 months (95% CI, 1.6–2.3) for TAS102 monotherapy, and 2.1 months (95% CI, 1.6–2.3) for regorafenib monotherapy. The hazard ratios were 0.57 (95% CI, 0.45–0.73) for TAS102 plus BEV versus TAS102 monotherapy and 0.44 (95% CI, 0.34–0.58) for TAS102 plus BEV versus regorafenib monotherapy. On multivariate analysis, TAS102 plus BEV was independently correlated with better OS and PFS. No unexpected adverse events were observed in any group. Conclusion: Our study shows that OS and PFS are longer in patients treated with TAS102 plus BEV than in those treated with TAS102 or regorafenib monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
- Author
-
Hasegawa, Hiroko, Taniguchi, Hiroya, Nakamura, Yoshiaki, Kato, Takeshi, Fujii, Satoshi, Ebi, Hiromichi, Shiozawa, Manabu, Yuki, Satoshi, Masuishi, Toshiki, Kato, Ken, Izawa, Naoki, Moriwaki, Toshikazu, Oki, Eiji, Kagawa, Yoshinori, Denda, Tadamichi, Nishina, Tomohiro, Tsuji, Akihito, Hara, Hiroki, Esaki, Taito, and Nishida, Tomohiro
- Abstract
FMS‐like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis. However, the oncogenic role of FLT3 amplification in patients with metastatic colorectal cancer (mCRC) remains unclear. Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications. Tumor tissue samples from 2329 patients were sequenced using NGS in the Nationwide Cancer Genome Screening Project in Japan. The effects of clinicopathological features, co‐altered genes, prognosis, and efficacy of regorafenib were investigated. Between April 2015 and June 2018, 85 patients with mCRC with FLT3 amplification were observed. There were no differences in baseline characteristics between patients with or without FLT3 amplification. The frequency of RAS or other gene co‐alterations was inversely correlated with the copy number status. Median survival time in patients with FLT3 amplification was significantly shorter compared with those with non‐FLT3 amplification. Further investigations of FLT3 amplification as a potential treatment target in mCRC are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel.
- Author
-
Fujii, Satoshi, Magliocco, Anthony M., Kim, Jihun, Okamoto, Wataru, Kim, Jeong Eun, Sawada, Kentaro, Nakamura, Yoshiaki, Kopetz, Scott, Park, Woong-Yang, Tsuchihara, Katsuya, Kim, Tae Won, Raghav, Kanwal, and Yoshino, Takayuki
- Subjects
NUCLEOTIDE sequencing ,EPIDERMAL growth factor receptors ,COLORECTAL cancer ,METASTASIS ,EARLY detection of cancer - Abstract
PURPOSE: ERBB2 amplification (human epidermal growth factor receptor 2 positivity [HER2
+ ]) in metastatic colorectal cancer (mCRC) has important therapeutic implications that necessitate the need for accurate diagnostics. The study purpose was to establish and validate harmonized diagnostic criteria for HER2+ mCRC among 3 groups (GI-SCREEN-Japan, NCTN-SWOG-USA, and Korea). PATIENTS AND METHODS: We assessed HER2 status by immunohistochemistry (IHC), ERBB2/CEP17 ratio, gene copy number (GCN) by fluorescence in situ hybridization (FISH), and copy number variation (CNV) using two targeted next-generation sequencing (NGS) panels. Tumor samples from 475 and 16 patients with mCRC in exploratory and validation cohorts, respectively, were used for cross-validation of the NGS panels. RESULTS: Consensus diagnostic criteria among the 3 groups for HER2+ mCRC were established as follows: IHC 3+ or IHC 2+ and ERBB2/CEP17 ratio by FISH ≥ 2.0, tumor content > 10% for surgically resected specimens, and necessary tumor content not defined for biopsy specimens. The median GCN and CNV for HER2+ patients were 10.9 and 27.7 compared with 2.5 (P <.0001) and 3.5 (P <.0001), respectively, in HER2-negative patients. These findings were validated in a validation cohort (GCN, 16.2 v 2.4 [ P =.0002]; CNV, 42.5 v 2.0 [ P =.0003]). GCN correlated with CNV in both cohorts (exploratory, r = 0.90; validation, r = 0.97; P <.0001). CNV in cross-validation of the 2 NGS panels also showed a strong correlation (r = 0.98; P <.0001). CNV in patients who fulfilled the consensus criteria was > 4.0 in all, which demonstrates the accuracy of the IHC/FISH criteria and cross-validation of NGS panels. CONCLUSION: We have established and verified harmonized diagnostic criteria for HER2+ and demonstrated consistency between IHC/FISH and CNV determined by NGS in mCRC. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
- Author
-
Kotani, Daisuke, Kuboki, Yasutoshi, Horasawa, Satoshi, Kaneko, Asumi, Nakamura, Yoshiaki, Kawazoe, Akihito, Bando, Hideaki, Taniguchi, Hiroya, Shitara, Kohei, Kojima, Takashi, Tsuji, Akihito, and Yoshino, Takayuki
- Subjects
BEVACIZUMAB ,COLORECTAL cancer ,METASTASIS ,FEBRILE neutropenia ,COHORT analysis - Abstract
Background: A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC in clinical settings.Methods: Records of patients with mCRC refractory to standard therapies who initiated trifluridine/tipiracil plus bevacizumab from January 2016 to March 2018 or trifluridine/tipiracil monotherapy from June 2014 to December 2015 were retrospectively reviewed at our institution.Results: Totally, 60 patients received trifluridine/tipiracil plus bevacizumab and 66 received trifluridine/tipiracil monotherapy. All patients had previously received standard chemotherapy. Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 2.3-5.1] in the trifluridine/tipiracil plus bevacizumab group and 2.2 months (95% CI, 1.8-2.6) in the trifluridine/tipiracil monotherapy group [hazards ratio (HR) 0.69; 95% CI 0.48-0.99]. PFS rate at 16 weeks was 46.6% for the trifluridine/tipiracil plus bevacizumab group and 33.9% for the trifluridine/tipiracil monotherapy group. Although a relatively higher incidence of grade ≥ 3 neutropenia was observed in the trifluridine/tipiracil plus bevacizumab group than that in the other group (50.0% vs. 40.9%, p = 0.371), the incidence of febrile neutropenia was not high (3.3% vs. 7.8%, p = 0.444).Conclusions: In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities.Trial Registration: Retrospectively registered. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
- Author
-
Nakamura, Yoshiaki and Yoshino, Takayuki
- Subjects
METASTASIS ,CANCER treatment ,EPIDERMAL growth factor ,BIOMARKERS ,BODY fluid examination ,CELLULAR signal transduction ,DECISION making ,DNA ,DRUG resistance in cancer cells ,COLON tumors ,ENDOSCOPIC surgery ,GENETICS ,IMMUNOTHERAPY ,GENETIC mutation ,RESEARCH evaluation ,TRANSFERASES ,RECTUM tumors ,PHENOTYPES ,GENOMICS ,SEQUENCE analysis ,DIAGNOSIS ,THERAPEUTICS ,TUMOR treatment - Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
16. ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer.
- Author
-
Kotani, Daisuke, Nakamura, Yoshiaki, Fujisawa, Takao, Bando, Hideaki, Sakamoto, Naoya, Johns, Amber L, Park, Keunchil, Casolino, Raffaella, Yoshino, Takayuki, and Biankin, Andrew V
- Subjects
- *
INDIVIDUALIZED medicine , *COLORECTAL cancer , *HETEROGENEITY , *TUMORS - Published
- 2023
- Full Text
- View/download PDF
17. PS3-3 Post-operative genomic/epigenomic signatures of circulating tumor DNA and recurrence in colorectal cancer: COSMOS-CRC-01.
- Author
-
Nakamura, Yoshiaki, Tsukada, Yuichiro, Murano, Tatsuro, Matsuhashi, Nobuhisa, Shiozawa, Manabu, Kato, Takeshi, Oki, Eiji, Goto, Masahiro, Kagawa, Yoshinori, Kanazawa, Akiyoshi, Ohta, Takashi, Ouchi, Akira, Bando, Hideaki, Zuo, Xiaotong, Parsana, Princy, Price, Kristin, Ikematsu, Hiroaki, and Yoshino, Takayuki
- Subjects
- *
CIRCULATING tumor DNA , *CANCER relapse , *DISEASE relapse , *COLORECTAL cancer - Published
- 2022
- Full Text
- View/download PDF
18. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
- Author
-
Nakamura, Yoshiaki, Hattori, Naoko, Iida, Naoko, Yamashita, Satoshi, Mori, Akiko, Kimura, Kana, Yoshino, Takayuki, and Ushijima, Toshikazu
- Subjects
- *
COLON cancer treatment , *BRAF genes , *MITOGEN-activated protein kinases , *APOPTOSIS , *REGULATOR genes , *ANTHROPOMETRY , *ANTINEOPLASTIC agents , *AZEPINES , *CELL cycle , *CELL physiology , *CELLS , *CELLULAR signal transduction , *COLON tumors , *DISEASE susceptibility , *DOSE-effect relationship in pharmacology , *HETEROCYCLIC compounds , *MICE , *GENETIC mutation , *SULFONAMIDES , *TIME , *TRANSFERASES , *PHENOTYPES , *INDOLE compounds , *PROTEIN kinase inhibitors , *PHARMACODYNAMICS - Abstract
Bromodomain and extra-terminal (BET) inhibitors suppress super-enhancers and show cytotoxicity against multiple types of tumors. However, early clinical trials with BET inhibitors showed severe hematopoietic toxicities, highlighting the need for sensitive tumors and rational combination strategies to enhance their therapeutic potential. Here, we identified colon cancer-specific super-enhancers that were associated with multiple oncogenic pathways, including the mitogen-activated protein kinase (MAPK) signaling pathway. Among the 14 colon cancer cell lines tested, their sensitivity to JQ1, a BET inhibitor, was not correlated with c-MYC expression. Three of four BRAFV600E-mutant cell lines were sensitive. Addition of JQ1 to vemurafenib, a specific mutant BRAF inhibitor, suppressed cell growth by arresting cell cycle progression and inducing apoptosis in the BRAFV600E-mutant cells. Mechanistically, the feedback activation of MAPK signaling pathway by vemurafenib was repressed by JQ1. Further, the addition of JQ1 to a BRAF inhibitor enhanced the in vivo anti-tumor effect. Thus, this study indicates the therapeutic potential of targeting of super-enhancers and mutant BRAF in patients with BRAFV600E-mutant colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer.
- Author
-
Kotani, Daisuke, Nakamura, Yoshiaki, Fujisawa, Takao, Bando, Hideaki, Sakamoto, Naoya, Johns, Amber L, Park, Keunchil, Casolino, Raffaella, Yoshino, Takayuki, Biankin, Andrew V, and ICGC-ARGO
- Subjects
- *
INDIVIDUALIZED medicine , *COLORECTAL cancer , *HETEROGENEITY , *TUMORS - Published
- 2022
- Full Text
- View/download PDF
20. O4-5 Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan.
- Author
-
Mishima, Saori, Kotani, Daisuke, Nakamura, Yoshiaki, Bando, Hideaki, Miyo, Masaaki, Hamabe, Atsushi, Watanabe, Jun, Hirata, Keiji, Akazawa, Naoya, Kataoka, Kozo, Yeh, Kun-Huei, Laliotis, George, Jurdi, Adham, Liu, Minetta, Taniguchi, Hiroya, Takemasa, Ichiro, Kato, Takeshi, Yoshino, Takayuki, and Oki, Eiji
- Subjects
- *
CIRCULATING tumor DNA , *COLORECTAL cancer , *DISEASE relapse - Published
- 2023
- Full Text
- View/download PDF
21. MO42-6 The clinical and molecular landscape of focal MET-amplified metastatic colorectal cancer patients.
- Author
-
Mishima, Saori, Kawazoe, Akihito, Nakamura, Yoshiaki, Lefterova, Martina, Odegaard, Justin, and Yoshino, Takayuki
- Subjects
- *
COLORECTAL cancer , *METASTASIS , *CANCER patients - Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.